| Document |
Document Title |
|
WO/1994/027609A1 |
Composition for use in androgenotherapy and having a favorable effect on the prostate hyperplasia. The composition is characterized in that it contains dihydrotestosterone in an administered quantity corresponding to a level of dihydrote...
|
|
WO/1994/026767A1 |
Androgen nucleus derivatives having specified substituents at the 17alpha position are disclosed for use as antiandrogens for the treatment of androgen-dependent diseases. In some preferred embodiments, the compound EM-250 is formulated ...
|
|
WO/1994/024146A1 |
Androgens and their derivates and analogs, such as anabolic agents, are characterized by at least one substituent or substituent grouping with radical trapping properties. These compounds are used as androgen or anabolic agent substitute...
|
|
WO/1994/022878A1 |
An alkylating agent contains an aluminium reagent Alk3-mAlLm, in which Alk stands for a methyl, ethyl, n- or i-propyl, n-, i- or tert.-butyl, pentyl, hexyl, heptyl or octyl group, which may all also be branched, L stands for an ethoxy gr...
|
|
WO/1994/022491A1 |
New technetium and rhenium chelate compounds are disclosed, as well as a process for preparing the same, radiopharmaceuticals containing these compounds, conjugates of these compounds with substances which selectively accumulate in disea...
|
|
WO/1994/022492A1 |
New bifunctional chalcogen-atom interrupted chelators, pharmaceutical containing these compounds, their use in radiodiagnosis and radiotherapy as well as a process for producing these compounds are disclosed. In the compound having gener...
|
|
WO/1994/022497A1 |
Novel bifunctional chalcogenic-atom-discontinuous chelating agents, pharmaceutical preparations containing them, their use in radio diagnosis and radio therapy, and methods of preparing them. The invention concerns compounds of the gener...
|
|
WO/1994/020111A1 |
The present invention is directed to a method for preventing or reducing ischemia following injury, such as reperfusion injury following ischemia, cellular damage associated with ischemic episodes, such as infarctions or traumatic injuri...
|
|
WO/1994/020104A1 |
Compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein R1 is -H or C1-10 alkyl; R2 is -H or C1-10 alkyl; R3 is C1-10 alkyl, C2-10 alkenyl, C1-10 alkoxyl, cyano, or triphenylthio- C1-6 alkyl; and R4 is a ...
|
|
WO/1994/019365A1 |
The present invention relates to compounds of formula (I) wherein (x) and (y) are single or double bonds; A is (1) or (2); R and R3 are hydrogen or acyl; R1 is hydrogen or fluorine; and wherein: when (y) is a single bond, R2 is hydrogen,...
|
|
WO/1994/018982A1 |
Fertilization of an oocyte is prevented or inhibited by administering a fertilizing inhibitory amount of an antiprogestin to an ovulatory mammal in an amount which is insufficient to prevent ovulation but sufficient to inhibit fertilizat...
|
|
WO/1994/018224A1 |
A use of a steroid having general formula (I), wherein R1 represents O, (H, OH), or two hydrogen atoms; R2 is hydroxy, optionally etherified or esterified; R3 is (2-6 C) alkynyl, optionally substituted with hydroxy; R4 is CN or one of th...
|
|
WO/1994/016709A2 |
Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hypogonadism, dim...
|
|
WO/1994/015612A1 |
A method for the treatment of atherosclerosis by administering to a patient in need of anti-atherosclerotic treatment, an effective amount of 17 alpha-dihydroequilin, a C2-C6 alkanoyloxy ester thereof or a pharmaceutically acceptable sal...
|
|
WO/1994/010984A1 |
The invention relates to a transdermal therapeutic system containing the active agent 17-beta-estradiol and possibly other active agents with a layered structure from a substantially moisture and active agent-impermeable substrate, one o...
|
|
WO/1994/011386A1 |
Invented are 17alpha and 17beta-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-red...
|
|
WO/1994/011004A1 |
Invented are 17alpha and 17beta-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-red...
|
|
WO/1994/009024A1 |
The invention concerns a method of alkylating oestrone derivatives, the method being characterized in that a suspension of an oestrone derivative in dimethylformamide is prepared, carbonic acid diester and guanidine and/or an alkylguanid...
|
|
WO/1994/008588A1 |
A pharmaceutical composition containing 7-hydroxylated derivatives of natural steroid hormones having, if necessary, a 3beta hydroxyl function, for use as an immunity trigger or stimulant (hereinafter termed ''immunity effector''), parti...
|
|
WO/1994/006819A1 |
The proposal is for the novel 4,5;11,12-estradienes of general formula (I) in which the substituents W, R11, R14, R15, R16, R17alpha, R17beta, R18 have the meanings given in the description, and a process for their production. The novel ...
|
|
WO/1994/004553A1 |
Described is a method for the preparation of 1-methyl-3-keto-DELTA1,4-steroids of general formula (I) in which St represents the residue of a steroid molecule, the method being characterized in that a 3-keto-DELTA1,4-steroid of general f...
|
|
WO/1994/004555A1 |
New steroids with an annulated five-membered ring have general formula (I), in which Y stands for an oxygene or sulphur atom or for a sulfonyl group or for the groups (a) or (b), in which X stands for a hydrogen atom, a saturated, straig...
|
|
WO/1994/004157A1 |
A transdermal application agent is characterized in that it contains 3-keto-desogestrel, if required combined with one or two estrogens.
|
|
WO/1994/003176A1 |
Alzheimer\'s disease and immune deficiency disorders may be effectively treated by administering a therapeutic amount of a DELTA5-Androstene-3beta-ol-17-one having a C7 substituent selected from the group consisting of oxo, hydroxy and g...
|
|
WO/1994/000125A1 |
Invented are 17alpha and 17beta-alkylketone-3-carboxy aromatic A ring analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-re...
|
|
WO/1993/025672A1 |
The present invention relates to the measurement of estradiol using competitive immunoassay methods. The inventors unexpectedly discovered that estrone and its derivatives conjugated to a label is a particularly effective tracer when use...
|
|
WO/1993/025569A1 |
The invention concerns compounds of general formula (I), in which either X is a hydroxyimino group (= N$m(k)OH), a hydroxy group and a hydrogen atom, a C¿1?-C¿20? alkanoyloxy group and a hydrogen atom or two hydrogens atoms and A----B ...
|
|
WO/1993/023376A1 |
Described is a new process for producing 7beta-substituted-4-aza-5alpha-androstan-3-ones and related compounds which are 5alpha-reductase inhibitors, consisting of reducing the corresponding androsteneone with lithium and liquid ammonia,...
|
|
WO/1993/023053A1 |
Inhibitors of testosterone 5alpha-reductase activity, for example those of formula (I) wherein novel substituents are provided at the R4, R6, R7, R17alpha and/or R17beta positions are useful for the treatment of diseases whose progress i...
|
|
WO/1993/023039A1 |
Described are new 16-substituted and 7,16-disubstituted 4-aza-5alpha-androstan-3-ones and related compounds as 5alpha-reductase inhibitors.
|
|
WO/1993/022333A1 |
Invented are 17$g(a) and 17$g(b)-substituted acyl-3-carboxy aromatic A ring analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-$g...
|
|
WO/1993/021771A1 |
Abnormally elevated levels of IL-6 are associated with a number of pathologic disorders. Compositions comprised of DHEA congeners are useful for the treatment of an individual to reduce an abnormally eleveted IL-6 level.
|
|
WO/1993/021924A1 |
The invention concerns a drug for increasing the level of testosterone in the human body, the drug containing at least one testosterone precursor.
|
|
WO/1993/020823A1 |
The topical application to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutic amount of an androgen or androgen analogue is disclosed as a method of relieving the chronic and acute manifestation o...
|
|
WO/1993/020696A1 |
The present invention provides an improved means for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstenediol (AE...
|
|
WO/1993/018742A1 |
The invention concerns novel, non-therapeutic fragrance compositions and other compositions containing an odorant and a naturally occurring human pheromone. The invention also concerns fragrance compositions containing mixtures of natura...
|
|
WO/1993/018053A1 |
This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3alpha-hydroxy,3beta-substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereoselectiv...
|
|
WO/1993/017686A1 |
Menses regulation and, when desired, contraception is achieved at low doses of estrogen and progestin, which otherwise would create episodes of breakthrough bleeding and/or withdrawal amenorrhea, by periodically inducing menses with an a...
|
|
WO/1993/017036A1 |
This invention presents alkali metal salts of 8,9-dehydroestrone, salts of its sulfate ester, and stable compositions thereof, as well as processes for their production and use in estrogen replacement therapy and cardiovascular protection.
|
|
WO/1993/015103A2 |
Novel steroids having a 9alpha-hydroxy or a 9alpha-carbonate substituent can be prepared from 9alpha-hydroxyandrostenedione and can be utilized in the synthesis of commercially valuable corticosteroids such as betamethasone. The 9alpha-c...
|
|
WO/1993/014107A1 |
Invented is an improved process for the preparation of benzo esters and benzo acids. Also invented are novel intermediates used in said process.
|
|
WO/1993/014105A1 |
The invention relates to new 6-difluoromethylenandrostenones having formula (I) wherein the symbol -_-_-_ represents a double or single bond; R is hydrogen or C1-C4 alkyl; and A is a =C=O, =CH$(1,3)$OH or =CH$(1,3)$OR1 group, in which R1...
|
|
WO/1993/012137A1 |
Compounds of formula (I) in which the dotted line indicates the optional presence of a double bond joining the 6 and 7 positions, A is a divalent group having a chain of at least four atoms joining the oxy group and the group BX, which g...
|
|
WO/1993/010741A2 |
Inhibitors of sex steroid activity, for example those having general structure (A) may be used as part of a pharmaceutical composition to provide antiestrogenic effects and/or to suppress estrogen synthesis. Such pharmaceutical compositi...
|
|
WO/1993/010772A1 |
The invention is represented by a transdermal medicated patch for the extended release of 17beta-estradiol to the skin. The transdermal patch is formed by an outer covering, a matrix containing from 1 % to 5 % (w/w) 17beta-estradiol, and...
|
|
WO/1993/006066A1 |
A new methylating or ethylating agent, containing trimethyl aluminium or dimethyl zinc or triethyl aluminium as methyl or ethyl source, further contains catalytic amounts of one or several cuprous and/or cupric compounds. Also disclosed ...
|
|
WO/1993/005064A1 |
Novel steroid sulphatase inhibitors are disclosed as well as pharmaceutical compositions containing them for use in the treatment of oestrone dependent tumours, especially breast cancer. The novel steroid sulphatase inhibitors are: sulph...
|
|
WO/1993/005170A1 |
Described is a method of preparing 14$g(a)-hydroxy-4-androstene-3,17-dione with a culture of $i(Curvularia lunata). The method is characterized in that 4-androstene-3,17-dione is suspended in water and the suspension thus obtained fermen...
|
|
WO/1993/003732A1 |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid recept...
|
|
WO/1992/014474A1 |
Methods of treatment for osteoporosis in a human or other animal subject, comprising: administering a bone-active phosphonate to said subject, at a level of at least about 0.1 LED per day of said treatment; and administering an estrogen ...
|
